Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1920 2
1921 4
1922 1
1963 1
1964 1
1967 6
1968 4
1969 3
1970 6
1971 3
1972 4
1973 2
1974 3
1975 5
1976 3
1977 9
1978 7
1979 8
1980 10
1981 23
1982 9
1983 14
1984 22
1985 8
1986 14
1987 18
1988 26
1989 26
1990 19
1991 15
1992 34
1993 24
1994 26
1995 30
1996 36
1997 43
1998 42
1999 41
2000 42
2001 47
2002 54
2003 46
2004 55
2005 62
2006 49
2007 41
2008 62
2009 78
2010 85
2011 80
2012 103
2013 81
2014 66
2015 59
2016 67
2017 77
2018 49
2019 53
2020 70
2021 78
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

1,836 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: doi y. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
Carbapenem-Resistant Enterobacteriaceae.
Iovleva A, Doi Y. Iovleva A, et al. Among authors: doi y. Clin Lab Med. 2017 Jun;37(2):303-315. doi: 10.1016/j.cll.2017.01.005. Epub 2017 Mar 11. Clin Lab Med. 2017. PMID: 28457352 Free PMC article. Review.
Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study.
Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. Liu YY, et al. Among authors: doi y. Lancet Infect Dis. 2016 Feb;16(2):161-8. doi: 10.1016/S1473-3099(15)00424-7. Epub 2015 Nov 19. Lancet Infect Dis. 2016. PMID: 26603172
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG Jr, Paterson DL, Bonomo RA, Evans S; Antibacterial Resistance Leadership Group. van Duin D, et al. Among authors: doi y. Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783. Clin Infect Dis. 2018. PMID: 29020404 Free PMC article.
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. Doi Y, et al. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01897-20. doi: 10.1128/AAC.01897-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32958718 Free PMC article. Clinical Trial.
1,836 results